Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Current Deferred Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Current Deferred Revenue for 4 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue rose 14.34% to $4.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Sep 2025, up 14.34% year-over-year, with the annual reading at $4.4 million for FY2024, 76.85% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $4.6 million at Orchestra BioMed Holdings, up from $4.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $21.7 million in Q1 2022, with the low at $2.5 million in Q4 2023.
  • Average Current Deferred Revenue over 4 years is $5.6 million, with a median of $4.3 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue plummeted 75.44% in 2023, then skyrocketed 76.85% in 2024.
  • Over 4 years, Current Deferred Revenue stood at $6.4 million in 2022, then tumbled by 61.0% to $2.5 million in 2023, then surged by 76.85% to $4.4 million in 2024, then rose by 4.73% to $4.6 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $4.6 million, $4.5 million, and $3.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.